kaboosantiniib - rezultati iskanja

Jordanija - angleščina - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

opdivo 100mg/10ml inj 100 mg/10ml

مستودع أدوية الشرق شخشير - orient drug store co - nivolumab 100 mg/10ml - 100 mg/10ml

Jordanija - angleščina - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

opdivo 40mg/4ml inj 40 mg/4ml

مستودع أدوية الشرق شخشير - orient drug store co - nivolumab 40 mg/4ml - 40 mg/4ml

Izrael - angleščina - Ministry of Health

retevmo 40 mg

eli lilly israel ltd, israel - selpercatinib - capsules - selpercatinib 40 mg - selpercatinib - • metastatic ret fusion-positive non-small cell lung cancerretevmo™ is indicated for the treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer (nsclc).• ret-mutant medullary thyroid cancerretevmo is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy.• ret fusion-positive thyroid cancerretevmo is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

Izrael - angleščina - Ministry of Health

retevmo 80 mg

eli lilly israel ltd, israel - selpercatinib - capsules - selpercatinib 80 mg - selpercatinib - • metastatic ret fusion-positive non-small cell lung cancerretevmo™ is indicated for the treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer (nsclc).• ret-mutant medullary thyroid cancerretevmo is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy.• ret fusion-positive thyroid cancerretevmo is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).